Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.
Q1 clean EBIT missed consensus by 3% on weaker GT, but we believe its margin concerns were well addressed, and improved hypermarket sales relative to the market point to an encouraging trend. After years of weakness, BTT profitability also expanded. We have made minor estimate changes (cut 2025–2027e clean EBIT by c2–0%) and raised our target price to EUR21.5 (20.5), due to our higher conviction on improved GT market-share momentum, which serves as a valuation trigger in the investment case, in ...
A solid Q1 report included orders and sales up 10% and 3% organically YOY, respectively, and an adj. EBIT margin of 19.9%; however, this included a 190bp FX boost, and we believe underlying margins could remain under pressure until the service mix improves. Albeit with increased uncertainty, management guided for mining demand to remain strong but construction to remain weak near-term. We have trimmed our 2025–2027e sales and adj. EBIT by 2% (FX-related) but reiterate our HOLD and SEK220 target ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.